BICO Group AB Class B (CLLKF)
OTHER OTC:CLLKF
Want to see CLLKF full AI Analyst Report?
CLLKF Stock Chart & Stats
$1.98
$0.10(3.47%)
At close: 4:00 PM EST
$1.98
$0.10(3.47%)
Day’s Range― - ―
52-Week Range$1.60 - $4.14
Previous CloseN/A
Volume500.00
Average Volume (3M)167.00
Market Cap
$164.28M
Enterprise Value$1.65B
Total Cash (Recent Filing)$744.30M
Total Debt (Recent Filing)$690.60M
Price to Earnings (P/E)―
Beta0.39
Next Earnings
Aug 25, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding69,074,900
10 Day Avg. Volume250
30 Day Avg. Volume167
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.85
Price to Sales (P/S)0.99
P/FCF Ratio26.97
Enterprise Value/Market Cap10.06
Enterprise Value/Revenue1.11
Enterprise Value/Gross Profit2.46
Enterprise Value/Ebitda-1.55
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.25
Revenue Forecast (FY)$169.97M
Bulls Say, Bears Say
Bulls Say
Strengthened Cash Position After EUR 40m Bond And Convertible SettlementA pro forma cash buffer of ~SEK 670m provides durable financial flexibility to fund R&D, commercial initiatives and bolt‑on M&A under the BICO 2.0 plan. This reduces short‑term refinancing risk and supports multi‑quarter execution of product and software investments.
Quarterly Margin Recovery And Positive Operating Cash FlowQ4’s move to positive adjusted EBITDA and operating cash flow signals structural improvement in cost discipline and operational leverage. Sustained quarter‑on‑quarter EBITDA conversion would underpin cash generation capacity and fund reinvestment without recurring capital raises.
Product, AI And Partnership Momentum Driving Recurring Revenue PotentialNew software/AI offerings and strategic partnerships shift revenue mix toward higher‑margin, recurring streams and strengthen commercial reach. Over 2–6 months, successful adoption of these tools increases customer stickiness and improves lifetime revenue per install.
Bears Say
Deep, Recurring Net Losses And Very Negative Net MarginPersistently large net losses and a ~-70% net margin erode equity and limit strategic optionality. Even with short‑term cash buffers, ongoing negative profitability undermines sustainable reinvestment and heightens risk of additional financing if margins do not normalize.
Declining Sales And Weak Organic Growth For The YearA full‑year organic decline of -8% reflects structural demand headwinds for instrument‑heavy products. Continued top‑line contraction reduces scale benefits, constrains margin recovery, and makes multi‑quarter turnaround dependent on sustained end‑market recovery.
Lab Automation Underperformance And Legacy Project ChargesLab Automation is a strategic core yet showed steep organic decline and negative EBITDA, exacerbated by legacy project restatements. Persistent execution issues in this high‑value segment threaten revenue recovery and delay realization of higher‑margin recurring software sales.
BICO Group AB Class B News
CLLKF FAQ
What was BICO Group AB Class B’s price range in the past 12 months?
BICO Group AB Class B lowest stock price was $1.60 and its highest was $4.14 in the past 12 months.
What is BICO Group AB Class B’s market cap?
BICO Group AB Class B’s market cap is $164.28M.
When is BICO Group AB Class B’s upcoming earnings report date?
BICO Group AB Class B’s upcoming earnings report date is Aug 25, 2026 which is in 116 days.
How were BICO Group AB Class B’s earnings last quarter?
BICO Group AB Class B released its earnings results on Apr 29, 2026. The company reported -$0.187 earnings per share for the quarter, missing the consensus estimate of -$0.108 by -$0.078.
Is BICO Group AB Class B overvalued?
According to Wall Street analysts BICO Group AB Class B’s price is currently Overvalued.
Does BICO Group AB Class B pay dividends?
BICO Group AB Class B does not currently pay dividends.
What is BICO Group AB Class B’s EPS estimate?
BICO Group AB Class B’s EPS estimate is -0.08.
How many shares outstanding does BICO Group AB Class B have?
BICO Group AB Class B has 69,074,900 shares outstanding.
What happened to BICO Group AB Class B’s price movement after its last earnings report?
BICO Group AB Class B reported an EPS of -$0.187 in its last earnings report, missing expectations of -$0.108. Following the earnings report the stock price went up 10.243%.
Which hedge fund is a major shareholder of BICO Group AB Class B?
Currently, no hedge funds are holding shares in CLLKF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BICO Group AB Class B
BICO Group AB (publ) operates as a bio convergence company in North America, Europe, Asia, and internationally. It operates through two segments, Laboratory Solutions and Bioautomation. The Laboratory Solutions segment offers 3D bioprinters, hybrid microscopes, single-cell dispensing instruments, and liquid handling instruments, as well as services and related consumables, such as bioinks, reagents, microscope lenses, software, printheads, and 3D reconstructed human tissues for applications in regulatory testing. This segment also offers services in 3D cell culture, 3D tissue imaging, multiplex imaging, and digital pathology to pharmaceutical and biotechnology companies. The Bioautomation segment offers products in precision dispensing and biosensor technology to the industrial customer; and diagnostics automation and advanced robotics solutions for the medical and diagnostic industries. In addition, it offers core industrial ecosystem, tissue engineering, multi-omics, cell line development, and diagnostics solutions. It primarily serves medical, pharmaceutical, and cosmetic industries. The company was formerly known as Cellink AB (publ) and changed its name to BICO Group AB (publ) in August 2021. BICO Group AB (publ) was founded in 2016 and is based in Gothenburg, Sweden.
CLLKF Company Deck
CLLKF Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced picture: the company executed its strategic repositioning (BICO 2.0), strengthened its cash position through a EUR 40m bond issuance, reduced debt and demonstrated a clear Q4 recovery with strong margins and Biosero momentum. However, full-year financials were weak (organic sales -8%, adjusted EBITDA only SEK 5m, Lab Automation full-year decline -26% and negative EBITDA), and the business faced notable macro headwinds (US academia funding cuts, FX pressure and cautious CapEx). Product launches, partnerships and AI-enabled offerings provide a foundation for growth, but near-term performance still reflects industry and legacy operational challenges.View all CLLKF earnings summariesTechnical Analysis
CellaVision AB
―
Senzime AB
―
Bactiguard Holding AB
―
C-Rad AB Class B
―
Sedana Medical AB
―
Ownership Overview
―
Insiders
0.02% Mutual Funds
1.56% Other Institutional Investors
96.61% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---